GlassScriptPhysician profile
Jamie P Ucci
NPI 1174116735
$1,118.47
in general payments reported to CMS, 2019-2025
22 companies · $607 in 2025
The $607 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $50.98 · 2024: $304 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $154.24 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Edwards Lifesciences Corporation | $123.08 | 2025 | Pascal |
| Pfizer INC. | $103.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $82.42 | 2024-2025 | Breztri, Farxiga |
| Si-Bone, INC. | $71.71 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.13 | 2021 | |
| Glaxosmithkline, LLC. | $59.76 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $56.52 | 2025 | |
| Abbvie INC. | $56.49 | 2024-2025 | |
| Alkermes, INC. | $42.64 | 2021 | |
| Corcept Therapeutics | $38.51 | 2024 | Korlym |
| Medtronic, INC. | $34.91 | 2025 | Synchromedii, Kyphon Express II Kyphopak Tray |
| Exact Sciences Corporation | $32.27 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $31.70 | 2024 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $27.82 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.69 | 2025 | Eliquis |
| Xeris Pharmaceuticals, INC. | $21.99 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $21.66 | 2025 | Wegovy |
| Lundbeck LLC | $18.76 | 2021 | |
| Myovant Sciences INC. | $17.83 | 2022 | |
| Indivior INC. | $17.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Ucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.